Regeneron Pharmaceuticals reported successful Phase III trial results for cemdisiran, an siRNA therapeutic targeting complement factor 5, in generalized myasthenia gravis. The monotherapy significantly reduced complement factor 5 levels and improved clinical symptoms, outperforming combination treatments. The company plans to file for FDA approval in early 2026 amid a competitive neuromuscular disease therapeutic landscape. The advancement supports Regeneron's growing neurology portfolio and highlights the potential of RNA interference in autoimmune conditions.